In the UK we talk a great deal about “living longer”, but much less about how we are living those extra years. The latest OECD data put average UK life expectancy at around 81 years, slightly below the OECD average, and, more worryingly, healthy life expectancy has stalled or gone into reverse for many people. In other words, our lifespan is edging up, but our healthspan (the years we spend with enough physical and cognitive reserve to live life on our own terms) is under pressure.
As the health scientist behind Second Prime® at GHS Clinics Cheltenham, I would argue that this gap between lifespan and healthspan is the defining health issue for people in midlife today.
In longevity, the real prize is not extra years on the clock, but extra years in which you are fully yourself.
This first article in our longevity series sets out the landscape: what healthspan actually means, what the science is telling us about ageing, and why your forties and fifties are the critical window to act, not in the grip of a “midlife crisis”, but with a clear, evidence-based strategy.
Lifespan versus healthspan: the UK picture
Lifespan is simple: the number of years from birth to death. Healthspan is trickier, but far more useful. The World Health Organisation defines healthy ageing as “the process of developing and maintaining the functional ability that enables wellbeing in older age”. It is less about a specific birthday and more about whether you can do what matters to you – work you find meaningful, relationships you value, physical and cognitive activities you enjoy.
In England, healthy life expectancy at birth has fallen over the last decade. Office for National Statistics data show that between 2011–2013 and 2020–2022, healthy life expectancy dropped by around nine months for men and over a year for women. Inequalities are stark: women in the most deprived areas now spend only about two-thirds of their lives in good health, compared with more than four-fifths in the most affluent areas.
Put bluntly, we are adding years to life, but not reliably adding life to those years, and some communities are losing ground on both. This is the backdrop against which any serious conversation about longevity, healthy ageing and “optimal performance in midlife” must sit.
What science now tells us about ageing
For most of the 20th century, ageing was seen as inevitable wear and tear. The biology was hazy. That changed with a series of landmark discoveries, several of which are directly relevant to how we designed Second Prime®.
In the 1960s, Leonard Hayflick and Paul Moorhead showed that normal human cells do not divide indefinitely in culture; they undergo a finite number of divisions and then enter a non-dividing state. This observation, now known as the Hayflick limit, helped to establish the concept of cellular senescence, cells that are alive but no longer functioning optimally, secreting inflammatory signals that can damage their surroundings.
Fast-forward to the 2010s and Steve Horvath’s work on DNA methylation, tiny chemical tags on the genome that change in a remarkably predictable way with age. His “epigenetic clock” uses methylation at 353 sites in the genome to estimate biological age across multiple tissues with impressive accuracy. Subsequent work has tied these epigenetic clocks to risk of mortality, frailty and age-related disease, suggesting that they capture something meaningful about the biology of ageing over and above the number of birthdays you have had.
Taken together, this line of research makes an important point for anyone thinking about longevity:
You do not have a single age, in fact, you have many. Your chronological age, your cellular age, your immune age, your vascular and cognitive age can all move at different speeds.
This is close to what journalists mean when they talk about “different types of ageing”, and it aligns with our Second Prime® framework, which treats cognitive load, metabolic function, gut–brain signalling and neuroendocrine regulation as interconnected but semi-independent domains of ageing risk.
Can we slow, or even reverse, biological age?
The obvious question is whether we can do anything about these biological clocks.
Randomised trials are beginning to offer cautious optimism. A large European study, DO-HEALTH, recently reported in Nature Aging that in older adults, a daily omega-3 supplement over three years led to a modest but measurable slowing of biological ageing, around three to four months, as assessed by several epigenetic clocks. The effect was strongest when omega-3 was combined with vitamin D and a simple home-based exercise programme. Independent experts, including in the UK, have been careful to point out that these are small shifts and that changing DNA methylation patterns does not automatically translate into fewer heart attacks or longer lives, but the direction of travel is encouraging.
If there is one healthspan intervention with more robust evidence, it is strength training in later life. A 2025 meta-analysis of randomised controlled trials in older adults with osteosarcopenia (combined low bone and muscle mass) found that strength training significantly increased skeletal muscle mass and grip strength, improved aspects of physical performance, and in some trials was associated with improved bone density compared with inactive controls. Observational and interventional work converges on the same conclusion: maintaining muscle and strength is critical to preserving independence and reducing frailty. UK guidance echoes this, with the NHS and Age UK both emphasising that adults over 65 should include strength and balance work at least twice a week to reduce falls and support healthy ageing.
From a clinical longevity perspective, this matters more than it might sound. Loss of muscle and power in the 60s and 70s is not just a nuisance; it underpins loss of mobility, increased falls, and a cascade of dependence that shortens healthspan long before it shortens lifespan.
If you are over 40, investing in strength, balance and recovery is one of the most powerful healthspan decisions you can make.
At the more experimental end of the spectrum, work from Claudia Cavadas and colleagues in Coimbra has highlighted the role of senescent cells, including in the skin, as active drivers of systemic ageing. A 2025 mouse study showed that transplanting senescent skin cells into young animals accelerated frailty and cognitive decline, while earlier work has mapped how senescent cells in skin can send “ageing signals” to other organs. These findings help explain why senolytic and senomorphic drugs, which aim to clear or modulate senescent cells, are being explored as potential longevity therapies.
It is important, however, to keep our feet on the ground. Senolytics are not yet part of routine clinical care. The responsible stance, in my view, is to use this science to understand mechanisms and refine lifestyle and clinical interventions we know are safe, while watching the pharmacological frontier closely.
How long can humans live, and does it matter?
A separate body of work focuses on the outer limits of human lifespan. Analyses of super-centenarian data by Jan Vijg and colleagues suggest that the maximum human lifespan may cluster around 115–120 years, with little evidence so far that this ceiling is shifting dramatically, even as more people survive into their 80s and 90s.
There is debate about the exact numbers, and new data continue to emerge, but for a UK reader in midlife the practical implication is straightforward. Barring radical breakthroughs, it is unlikely that most people alive today will routinely live to 150. What is far more tractable is whether the years from, say, 50 to 80 are dominated by vitality and contribution, or by preventable morbidity, polypharmacy and repeated hospital admissions.
In other words, healthspan is the lever we can realistically pull; extreme lifespan extension remains speculative.
The “midlife crisis” is it a crisis, or critical window?
The phrase “midlife crisis” still looms large in popular culture, bound up with sports cars and sudden career changes. The data tell a more nuanced story. Large cohort studies suggest that only about 10–20% of people report something that fits a classic crisis pattern, and newer work argues that the iconic midlife “unhappiness hump” is flattening or shifting as mental health challenges emerge earlier in life.
That does not mean midlife is easy. It is a period characterised by intense role strain for example; leading teams at work, supporting ageing parents, often still parenting children, carrying a disproportionate load of financial and emotional responsibility. These pressures show up very clearly in our own Second Prime® System data at GHS Clinics, and in wider research linking midlife physical activity, blood pressure and stress to later-life cognitive and physical outcomes.
From a longevity standpoint, I prefer to think of midlife not as a crisis, but as the moment when your accumulated biological risk either quietly compounds, or is deliberately redirected.
Second Prime®: a healthspan-first lens on longevity
This is precisely where the Second Prime® model sits.
Second Prime® assumes that you are not a collection of isolated organ systems, but a complex network of interacting domains: cognitive and psychological load, energy and recovery, metabolic and movement health, gut–brain and immune signalling, self-perception and identity, and neuroendocrine regulation. Instead of asking “how old are you?”, we ask “which parts of you are ageing fastest, and why?”
We combine detailed history and psychosocial mapping with biometrics, advanced blood panels and, where appropriate, imaging and genomics, to build a picture of your personal ageing trajectory. The aim is not to promise that we will make you live to 120, or to “reverse ageing” in a simplistic sense. That would neither be honest nor scientifically defensible. Rather, we use the best available evidence on muscle and bone health, on cardiometabolic risk, on sleep, stress and cognitive reserve, on senescence biology and epigenetic clocks to identify which levers are most likely to extend your healthspan and reduce your risk of age-related decline.
You cannot control everything about ageing, but you can control far more than you have been led to believe, provided you start before the wheels come off.
For many of our clients this means quite prosaic, but precisely targeted, actions: structured strength and balance training tailored to their current function; nutritional shifts that support muscle and metabolic health rather than the latest diet trend; sleep and cognitive-load interventions informed by their actual lived experience rather than generic resilience advice; and, where clinically indicated, evidence-based pharmacology aligned with UK guidelines.
Where this series goes next
In future articles, I will explore specific themes in more depth: why strength training becomes non-negotiable after 40; what the new science of epigenetic and “multi-system” ageing really means for an individual in Cheltenham trying to stay well; how to think about senescent-cell-targeting therapies without getting lost in hype; and how to replace the idea of a midlife crisis with a structured Second Prime® strategy.
For now, the message is simple. In the UK we are living longer than previous generations, but not necessarily better. The science of ageing has moved from vague metaphor to measurable biology. The interventions that reliably extend healthspan are not exotic, they are grounded in muscle, movement, metabolic stability, psychological load and social context. And midlife is when the return on getting them right is at its peak.
Your Second Prime® s a decision about how you want the second half of your life to feel.